相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Ubiquitin Makes Its Mark on Immune Regulation
Barbara A. Malynn et al.
IMMUNITY (2010)
Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease
A. Bouazzaoui et al.
GENES AND IMMUNITY (2009)
Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity
Xiangling Wang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Graft-versus-host disease
James L. M. Ferrara et al.
LANCET (2009)
Impaired Effector Memory T-Cell Regulation Facilitates Graft Versus Host Disease in CCR7-Deficient Bone Marrow Transplant Chimeras
Saskia C. A. de Jager et al.
TRANSPLANTATION (2009)
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells
Carsten Berges et al.
IMMUNOLOGY (2008)
A New Approach to the Blocking of Alloreactive T Cell-Mediated Graft-versus-Host Disease by In Vivo Administration of Anti-CXCR3 Neutralizing Antibody
Shan He et al.
JOURNAL OF IMMUNOLOGY (2008)
The Erk2 MAPK Regulates CD8 T Cell Proliferation and Survival
Warren N. D'Souza et al.
JOURNAL OF IMMUNOLOGY (2008)
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
Changyou Li et al.
MOLECULAR CANCER THERAPEUTICS (2008)
CCR7 and its ligands:: balancing immunity and tolerance
Reinhold Foerster et al.
NATURE REVIEWS IMMUNOLOGY (2008)
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
D. A. Fennell et al.
ONCOGENE (2008)
CXCL 10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation
Karen P. Piper et al.
BLOOD (2007)
Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse
B. Wysoczanska et al.
TRANSPLANTATION PROCEEDINGS (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Ubiquitin and ubiquitin-like proteins in cancer pathogenesis
Daniela Hoeller et al.
NATURE REVIEWS CANCER (2006)
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation
Alessio Nencioni et al.
BLOOD (2006)
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Tommaso Caravita et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
B Blanco et al.
BLOOD (2006)
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, velcade)
Lana Y. Schumacher et al.
JOURNAL OF IMMUNOLOGY (2006)
Increase of CCR7- CD45RA+ CD8 T cells (TEMRA) in chronic graft-versus-host disease
M D'Asaro et al.
LEUKEMIA (2006)
NF-κB as a target for the prevention of graft-versus-host disease:: comparative efficacy of bortezomib and PS-1145
S Vodanovic-Jankovic et al.
BLOOD (2006)
A revision of Billingham's tenets: The central role of lymphocyte migration in acute graft-versus-host disease
R Sackstein
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Pathophysiology of graft-versus-host disease
JLM Ferrara et al.
SEMINARS IN HEMATOLOGY (2006)
In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets
A Beilhack et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation
M Jaksch et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Blockade of CXCR3 receptor: Ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome
GC Hildebrandt et al.
JOURNAL OF IMMUNOLOGY (2004)
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
K Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4+ effector memory cells relative to central memory cells
K Yamashita et al.
BLOOD (2004)
Role of CXCR3-induced donor T-cell migration in acute GVHD
U Duffner et al.
EXPERIMENTAL HEMATOLOGY (2003)
Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays
T Ichiba et al.
BLOOD (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)